

Early Detection of Osteoarthritis in the Rat With an Antibody Specific to Type II Collagen Modified by Reactive Oxygen Species

Anne Gigout

Galapagos NV

Donata Harazin

Merck & Co Inc

Louise M. Topping

Kennedy Institute of Rheumatology

Sven Lindemann

Merck KGaA

Christian Brenneis

Merck KGaA

Ahuva Nissim (✉ a.nissim@qmul.ac.uk)

Queen Mary University of London <https://orcid.org/0000-0003-4617-0905>

Research article

Keywords: reactive oxygen species, osteoarthritis, hypertrophy, collagen type II, collagen type X

Posted Date: July 27th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-46998/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Arthritis Research & Therapy on April 14th, 2021. See the published version at <https://doi.org/10.1186/s13075-021-02502-1>.

Abstract

Background

Osteoarthritis (OA) is a disease of the whole joint, with articular cartilage breakdown as a major characteristic. Cartilage degradation is mostly driven by chondrocytes which produce inflammatory mediators, proteases and oxidants. Nevertheless, the early pathogenesis events are still unclear. We employed antibody that is specific to oxidative post-translationally modified collagen type II (anti-oxPTM-CII) to detect early cartilage pathogenic changes in two rat models of OA.

Methods

The animals underwent surgery for destabilization of the medial meniscus (DMM) and were sacrificed at 3, 5, 7, 14 and 28 days or anterior cruciate ligament transection with partial meniscectomy (ACLT + pMx) and were sacrificed after 1, 3, 5, 7 and 14 days. Joints were stained with toluidine blue and Saffron du Gatinais for histological scoring, anti-oxPTM-CII and anti-collagen type X antibodies (anti-CX).

Results

We observed oxPTM-CII staining as early as 1 or 3 days after ACLT + pMx or DMM surgeries respectively, before overt cartilage lesions were visible. It was located mostly in the deep zone of the medial tibial cartilage, in the pericellular and territorial matrix of hypertrophic chondrocytes and co-localized with CX staining. Both staining were weak or absent for the lateral compartment or the contralateral knees except at later timepoints.

Conclusion

The results demonstrate that oxidants production and chondrocytes hypertrophy occur very early in the onset of OA, possibly initiating the pathogenic events of OA. We propose to use anti-oxPTM-CII as an early biomarker for OA ahead or radiographic changes.

Background

Osteoarthritis (OA) is one of the leading causes of reduced quality of life worldwide, due to chronic pain and various degrees of disability. Although OA affects all the tissues of the articular joint, degradation and loss of articular cartilage is a central feature (1, 2). Cartilage degradation in OA results from a disruption in homeostasis due to activation of the chondrocytes by various factors that promote production of matrix degrading enzymes in excess of the capacity of the chondrocyte to replace damaged and degraded matrix components. The factors that activate chondrocytes to promote matrix degradation include excessive and abnormal mechanical loading, pro-inflammatory cytokines and

chemokines, as well as Wnt ligands and factors activating the innate immune system (1, 3). Many of these OA factors stimulate chondrocytes to produce reactive oxidants (ROS). ROS are utilized as secondary messengers in mediating intracellular signaling events that regulate expression of matrix degrading enzymes (4, 5) and pro-death cell signaling pathways, which compromise chondrocyte integrity and promote cartilage damage (6). The most abundant ROS produced by chondrocytes include superoxide, hydrogen peroxide, the reactive nitrogen species nitric oxide, and the nitric oxide derived product peroxynitrite.

Experimental OA models induced by joint instability have been highly valuable in identifying key pathogenic pathways in disease and for validating new treatments. They produce robust degradation of the articular cartilage, changes in the subchondral bone, and can be used to investigate pain-like symptoms. Widely used models of animal OA involve surgically induced instability of the knee (7). These models are characterized by an acute injury to the joint that causes mechanical instability, resulting in OA. Many types of operations on various animals have been developed, including cruciate or collateral ligament transections and partial or total meniscectomies on dogs, goats, rabbits, and rodents. Most of the studies detect mild changes in the articular cartilage at 2 to 4 weeks postoperatively. For example, in the anterior cruciate ligament transection (ACLT) model, cartilage destruction is seen 2–4 weeks after surgery (8). Alternatively, when OA is induced by destabilization of the medial meniscus (DMM), structural change progression is slower (9–11). Currently, the size of the animal precludes prospective assessment of disease by conventional radiographic approaches, and disease is assessed by serial histology of the joint, which is time consuming, costly and requires large number of animals as they need to be culled at each experimental timepoint under investigation. Powerful non-invasive small-animal imaging techniques for longitudinal studies are therefore highly desirable for preclinical validation studies as well as for detection and monitoring of early OA in patients.

We previously developed a panel of human single chain fragment variable (scFv) that bind specifically to oxidative post-translationally modified collagen type II (oxPTM-CII) (12). We showed that anti-oxPTM-CII: i) binds specifically to arthritic cartilage from patients with RA and OA; ii) stains cartilage in murine models of inflammatory arthritis (antigen induced arthritis (AIA) and OA, namely DMM; iii) localizes in the arthritic joint in vivo in a mouse model of AIA and DMM following systemic administration of labelled anti-oxPTM-CII with Alexa Fluor 680 or Cy5.5 (12, 13); and iv) was able to target therapeutic scaffold specifically to arthritic joint (14).

In the current study, we evaluate longitudinally the presence of oxPTM-CII staining in early OA in two rat models: DMM and ACLT + pMx. Our goal was to possibly unravel some of the very early events in OA and evaluate the possibility to detect the initiation of the disease before the appearance of cartilage lesions. Rats were sacrificed 3, 5, 7, 14 and 28 days after DMM and 1, 3, 5, 7 and 14 days after ACLT + pMx surgery and the lateral and contralateral knees were stained with toluidine blue and Saffron du Gatinais, or for oxPTM-CII and type X collagen (CX). OxPTM-CII and CX were detectable already at the earliest time points in the medial tibial cartilage and strongly co-localize. We conclude that i) ROS production and

increased type X collagen expression is an early event in OA and prefigure cartilage lesion; and ii) Anti-oxPTM-CII detection could be a powerful tool to detect initiation of OA.

Method

Antibody preparation

Anti-oxPTM-CII scFv, was expressed in HB2151 bacteria as described (15). ScFv was converted to full length antibody by cloning V_H domain into pFUSEss-CHlg-hG1e3, and V_L domain into pFUSEss-CLlg-hk (InvivoGen). Plasmid DNA was isolated using a QIAFilter Plasmid Maxi Kit according to the manufacturer's instruction (Qiagen). Following transient expression in Expi293F Expression System according to the manufacturer's instructions (ThermoFisher Scientific), supernatants were collected and purified using protein A Sepharose CL-4B (GE Healthcare). The ability to retain specific binding of anti-oxPTM-CII over native CII was assessed by ELISA as described (12).

Animal models

Male Lister Hooded (CrI:LIS) outbred SPF rats (8–9 weeks with a weight of 150–175 g from Charles River) were housed in colony cages as described in Brenneis, Westhof et al. 2017 with 48 rats/cages at the start of the study. After 4 weeks of acclimatization, rats underwent surgery under anesthesia. the ACLT + pMx was performed as described elsewhere (Brenneis, Westhof et al. 2017) except that only 50% of the meniscus was removed. For destabilization of the medial meniscus (DMM), a skin incision was made from distal the patella proximal to the tibial plateau (of the right joint). The muscle layer was opened in knee flexion with a scalpel and prepared to visualize the medial meniscus tendon which was ligated with a scissors. Finally, the joint capsule, associated muscles and connective tissue were sutured in layers. For postsurgical analgesia, rats received meloxicam (0.5 mg/kg s.c.; Metacam injection solution, Boehringer Ingelheim). After housing for different time periods after surgery, rats (9–10 per timepoints) were humanely euthanized by transthoracic heart puncture in isoflurane anaesthetized rats.

Histology and scoring

The ipsilateral knees of all animals and contralateral knees of two animals per timepoints (N = 10) were fixed for seven days in paraformaldehyde (VWR) 4% in phosphate-buffered saline (PBS, VWR) and decalcified for six weeks in formic acid (Sigma-Aldrich) 4% in PBS and embedded in paraffin. Coronal sections of 7 μ m (including medial tibial plateau, femur condyle and menisci) were cut with a microtome within the weight bearing area. Every 35th sections were collected. The slides were deparaffinized and rehydrated, stained with toluidine blue (VWR, 0.05% in PBS, 6 min) and Saffron du Gatinais (Morphisto GmbH, diluted 1:3 in absolute Ethanol, 1 min). Slides were dehydrated, coverslipped and after drying digitized using slide scanner SCN400 (Leica Microsystems). For histopathological grading a modified Makin score recommended by the osteoarthritis research society (modified from (16) was used with a maximum SUM score of 28 (sub-scores are described in supplementary material Table S1). Scanned slides were analyzed by two independent observers and the most severe lesion within the weight bearing

area for each rat was selected for evaluation. For each sub-score, the values from two consecutive slices were averaged to determine overall values for each animal.

Immunostaining

Single or double staining were realized for type X collagen (CX) and ROS-modified type II collagen (oxPTM-CII). For the ACLT + pMx study, two single staining were done, one for CX and one for oxPTM-CII. For the DMM study, to evaluate the co-localization of CX and oxPTM-CII a double staining was first realized. However, because the blue staining of CX was very dark and bot staining overlap, it was difficult to see clearly the brown staining of the oxPTM-CII. For this reason, for the DMM study an addition single staining for oxPTM-CII was realized.

For the CX staining, the slides were first deparaffinized and rehydrated. An epitope retrieval using Proteinase K (Leica Biosystems) was performed. Slices were subsequently incubated with a monoclonal mouse antibody specific for Collagen X (#1-CO097-05, Quartett) diluted 1:50, for 30 min at room temperature. For the detection, the Leica Polymer Refine Red Detection System (#DS9390, Leica Biosystems) was used where the RED dye was substituted by NBT/BCIP (#ab7468, Abcam). The type X collagen staining was realized using a fully automated immunohistochemistry stainer (Bond III, Leica Microsystems).

For the staining of oxPTM-CII, an epitope retrieval using HCl (Merck KGaA) 0.02% in ddH₂O, 37 °C, 15 min followed by 15 mg/mL Pepsin (Merck KGaA) in HCl 0.02%, 37 °C, 45 min) was performed. The slices were incubated with the anti-oxPTM CII antibody 6.5 µg/mL overnight at 4 °C and detected using Polink-2 Plus HRP human IgG with 3,3'-diaminobenzidin (DAB) (#D88, GBI Labs).

For both staining a negative control where the primary antibody was omitted was performed.

Statistical analysis

Data were analyzed with a Kruskal-Wallis test and corrected for multiple comparison with a Dunn's test. GraphPad Prism v7.00 was used.

Results

DMM surgery affects more profoundly and ACLT + pMx more strongly the medial tibial compartment.

After the DMM and the ACLT + pMx surgeries, osteoarthritis develops mostly in the medial tibial plateau and this area was scored according to the histochemical-histological scoring system modified from (16). For the DMM model, animals were sacrificed at days 3, 5, 7, 14 and 28. Because ACLT with meniscectomy results in more severe OA compared to DMM (9), earlier time points were chosen for this model and animals were sacrificed at days 1, 3, 5, 7 and 14. After DMM surgery, loss of matrix staining in cartilage was apparent already after three days as illustrated on Fig. 1A and on the matrix staining sub-score (Figure S1) but cartilage defects appeared only at day 28 in most of the animals (Fig. 1E and sub-score cartilage structure in Figure S1). Most of the other sub-scores such as cellularity, alteration of the

tidemark and thickening of the subchondral bone started to be evident at day 14. Small to medium-sized osteophytes were observed in a minority of animals 14 or 28 days after the surgery. As a result, the total histological score was significantly elevated at day 14 and 28 in comparison to the contralateral medial tibial plateau (Fig. 1) for this model. After the ACLT + pMx surgery, the total histological score (Fig. 1) was significantly elevated from the first day compared to the contralateral knee and this was mainly driven by the cartilage structure and the matrix staining sub-scores (Figure S2). The other sub-scores were barely affected, and no osteophyte was observed. The comparison of both models at days 3–14 shows that the total histological scores were higher (except at day 5) for the ACLT + pMx model, and this seems to be mostly driven by the higher sub-scores for cartilage structure and matrix staining. However, because more sub-scores were affected in the DMM compared to ACLT + pMx, it might indicate that in DMM induces more profound changes in the joint.

OxPTM type II collagen and CX signal in the deep zone are early markers of OA

ACLT + pMx and DMM knees were stained by anti-oxPTM-CII and antibody specific to CX (Fig. 2). For both the ACLT + pMx and DMM knees, a strong CX staining is observable in the deep zone located where matrix loss or cartilage damages were also visible. Otherwise, in the rest of the deep zone the staining was weak all along the tidemark. Similarly, most of the cartilage was negative for oxPTM-CII but a positive signal can be observed in the deep zone in the region where cartilage degradation occurred. Interestingly, both staining were already observable at early time points, before visible cartilage damages started to develop. Both staining were also particularly strong where hypertrophic chondrocytes in the deep zone were visible. In addition, in the DMM model at day 28 more severe damages could be observed. In this case, oxPTM-CII and CX staining extended beyond the deep zone at the damage site and the all depth of cartilage was positive for CX.

We also looked at the lateral tibial compartment of the operated knees (FigureS3) and the contralateral knees (Figure S4). For both the ACLT + pMx and DMM models at early timepoints (days 1 or 7 or days 3 or 14 respectively), the staining for CX and oxPTM-CII in the lateral tibial compartment were weak or not visible and this irrespectively of the histological score obtained on the medial side (Indicated in brackets Figure S3A). However, at day 14 in the ACLT + pMx model and day 28 in the DMM model signal for both collagens appeared. On the contrary to the medial tibial cartilage, the staining was not restricted to a specific location in the cartilage. These results illustrate that at later timepoints the disease progressed to the lateral side of the operated joint. The lateral tibial compartment was scored as well (Figure S3B). The histological scores were low in all groups and no difference could be observed to the contralateral lateral tibial compartment at all timepoint tested.

Similarly, the contralateral (Figure S4) knees showed only a weak CX and oxPTM-CII staining at day 1 or 3 in the ACLT + pMx or DMM models respectively but an increased staining intensity was visible on the medial side for both CX and oxPTM-CII after ACLT + pMx at day 14 and for oxPTM-CII after DMM at day 28. As for the ipsilateral knee, CX and oxPTM-CII were strictly localized in the deep zone around the large

hypertrophic chondrocytes in the medial tibial compartment, and the staining was more diffuse in the lateral tibial compartment.

Finally, condylar cartilage was found to be mostly negative for oxPTM-CII (not shown) but started to be positive when large damages develop on the tibial side (see example on Fig. 3D-E). Condylar cartilage was also weakly positive for CX, which was strictly localized in the deep zone. A stronger CX staining appeared with the progression of the disease but at later time points compared to the tibial cartilage (data not shown).

OxPTM-CII and CX staining partially co-localize.

Higher magnifications of the medial tibial cartilage from DMM knees are shown Fig. 3 for cartilage with matrix staining loss but no defect (Fig. 3A and B) or for cartilage with a small (Fig. 3C) or a large defect (Fig. 3D). An example for condylar cartilage is also shown (Fig. 3E). Only the DMM knees are shown as the double-staining for CX and oxPTM-CII enable to better determine whether both markers co-localized. In the cartilage with no apparent defect, CX and oxPTM-CII staining co-localized in the deep zone mostly in the pericellular and territorial matrix of the hypertrophic chondrocytes. In panel A, chondrocytes that were positive for oxPTM-CII but negative for CX can also be observed (see arrows). In cartilage presenting a small defect (Panel C), the pattern was similar. However, in the case of larger defect (panel D), CX staining was found in the interterritorial matrix and extended to the middle zone while oxPTM-CII staining extended to the middle and superficial zone. Interterritorial staining of oxPTM-CII was also observed in the middle and superficial zones in the area of the damaged fibrillar cartilage (Panel D). In addition, in the middle and superficial zones, cells positive for oxPTM-CII but not CX were observed (see arrows). These results indicate that oxPTM-CII and CX staining mainly co-localize (around the larger chondrocytes in the deep zone) in early OA but might show a slightly different pattern at later OA stages. Finally, condylar cartilage facing a large defect (here picture from panels D and E are from the same animal) was positive for both staining and the staining were observed in all zones of cartilage.

The growth plate and the meniscus are positive for oxPTM - CII

As expected, the growth plate and the calcified part of the meniscus were positive for CX (Fig. 4). These tissues were also found to be positive for oxPTM-CII. In these two tissues, both staining appear to co-localize.

Discussion

The ACLT + pMx (or tMx) and the DMM models are both surgically induced instability OA models that are broadly used to study disease progression. In the present study we investigated early disease progression for both models and evaluated the presence oxidized type II collagen in cartilage and its co-localization with type X collagen- a marker of chondrocyte hypertrophy.

We used ACLT + pMx and a DMM model in rats housed in colony cages enabling free movement of the animals (9, 17). In accordance with the results from others (9), the total histopathological scores were higher with the ACLT + pMx model than the DMM model for the same time points and the disease developed faster with the ACLT + pMx. Interestingly, when looking at the sub-scores, the ACLT + pMx influenced only two of them until day 14 (cartilage structure and matrix staining) while after DMM all sub-scores were affected possibly indicating a more profound effect on the joint.

Oxidative stress is known to play a major role in OA (2, 18). To investigate if oxidative stress is an early or late event in OA and to better understand how it affects cartilage and chondrocytes, we used an antibody against oxidized type II collagen (oxPTM-CII). Anti-oxPTM-CII was developed to recognize different forms of oxidized type II collagen and was demonstrated to bind human OA and RA cartilage but not healthy cartilage (12). OxPTM-CII was detected in the medial tibial cartilage of the operated knees as early as one and three days after ACLT + pMx and DMM surgeries respectively, and this before any cartilage damage was visible. Until 14 days after surgery, the staining localized in the deep zone in the pericellular and territorial matrix of large hypertrophic chondrocytes. When larger defects occurred however, oxPTM-CII extended to the interterritorial matrix through the complete depth of cartilage. The staining was absent from the lateral tibial and femoral condylar cartilage but with the progression of the disease staining became visible in these compartments as well (day 14 for ACLT + pMx, day 28 for DMM). This is in accordance with the observations from others (9, 19) that in these OA models, lesions develop primarily in the medial tibial plateau. We also looked at the contralateral knees and found that oxPTM-CII staining was absent or weak at early time points but started to appear at later time points. It indicates that the disease also starts to develop in the contralateral knee, possibly because animals change their gait inducing mechanical stress in the contralateral joint (20). This is expected to be accelerated in the colony housing since they perform here much more weight bearing activities (17). It was already demonstrated that under mechanical stress chondrocytes produce ROS (21). It is also known that removal or displacement of the meniscus increase peak stress in the medial compartment (22) and that cartilage normally covered by the meniscus possesses decreases load-bearing capacity and less resilience to damage compared to cartilage covered by menisci (23). We postulate that the DMM and the ACLT + pMx surgeries produce a strong mechanical stress in the tibial cartilage that was covered by the meniscus before the surgery resulting in ROS production (2) and the apparition of oxidized type II collagen. The localization of the staining corresponds probably to the zone where mechanical stress was the highest. It is also interesting to note that on the lateral compartment where the meniscus remained, and consequently mechanical stress was lower, the staining was more diffuse and not restricted to the deep zone. A similar pattern was observed in the medial condyles. Possibly, in medial tibial cartilage the production of ROS and the resulting oxPTM-CII does arise from excessive loading while on the lateral side and the condyles ROS production and oxPTM-CII staining might be rather due to the diffusion of ROS and other inflammatory components from the medial tibial cartilage to other joint compartments.

Because oxPTM-CII was predominantly found in the deep zone and ROS are known to stimulate chondrocyte hypertrophy (24, 25) we also evaluated if oxPTM-CII colocalizes with type X collagen (CX). Indeed, we observed a strong colocalization and both staining became more intense with disease

progression. We also observed that 28 days after DMM surgery CX staining extended to the complete depth of cartilage at a time when large defects were also observed. Previous studies also described an increased CX expression during OA (26, 27) and similarly to our observation, a pericellular staining in the deep zone and in advanced OA also in the middle zone was reported (27). However, to our knowledge the present study is the first one that shows an increase of CX expression early in the disease. Similarly, to oxPTM-CII, CX staining was detected before any apparent cartilage damage develops. At later time points (14 days for ACLT + pMx and 28 days for DMM), both staining did not co-localize anymore. We hypothesize that chondrocytes first produce ROS, which induces hypertrophy (24, 25) and subsequently lead to CX deposition. Possibly cells from the middle zone and superficial layer are more resistant to hypertrophy (28) increasing the delay between ROS production and CX production in these zones.

Our results are in accordance with previous observations that the localization of oxPTM-CII is predominantly in the ipsilateral joint and that it is detected ahead of cartilage structural changes (12, 13). In previous work we used Cy5.5-anti-ROS CII antibody or Cy5.5-anti-ROS CII scFv injected i.v. or i.a to detect OA changes in vivo with non-invasive imaging in DMM mice after 4 or 8 weeks. The present study demonstrates that labeled oxPTM-CII antibody or scFv could diagnose OA even earlier in the DMM model and could be used to monitor disease progression. Future longitudinal studies will need to assess the utility of anti-oxPTM-CII as a novel molecular imaging tool to both detect early onset and to longitudinally monitor OA in small animal models. If proven to be successful, anti-oxPTM-CII may be exploited for molecular imaging in parallel with future developments of MRI capabilities in human. Imaging with anti-oxPTM-CII may be interpreted in association with MRI/radiography for enhanced overall clinical management of patients, as well as improvement of outcome readouts in clinical trials.

In conclusion, oxPTM-CII and CX staining of ACLT + pMx and DMM rat knees showed that the disease starts extremely early (day 1 and 3 respectively) in the deep zone of tibial medial cartilage, and that the load-bearing zone that was covered by the meniscus before surgery was affected first. Our results confirm that chondrocyte hypertrophy is an integral part of the OA pathobiology and might be an initiating event of the disease. In addition, because oxPTM-CII and CX staining were strictly localized in the pericellular matrix at early timepoints, this study also supports the hypothesis that OA is a disease of the pericellular matrix (29, 30).

Conclusions

We propose that oxPTM-CII antibodies or oxPTM-CII scFv labeled with a fluorescent probe is a promising biomarker to detect OA initiation ahead of radiographic changes and monitor its progression.

List Of Abbreviations

Osteoarthritis (OA), **Collagen type II (CII)**, oxidative post-translationally modified collagen type II (oxPTM-CII), collagen type X (CX), anterior cruciate ligament transection with partial meniscectomy (ACLT + pMx), destabilization of the medial meniscus (DMM), reactive oxidants (ROS).

Declarations

Ethics approval and consent to participate

All procedures were approved by the animal protection authorities of the local district government (Regional Authorities of Hessen, Germany).

Consent for publication

Not applicable

Availability of data and materials

All data generated during this study are included in this published article, and in its supplementary information files, or are available from the corresponding author on reasonable request.

Competing interests

Anne Gigout, Sven Lindemann, Christian Brenneis and Donata Harazin were employees of Merck KGaA at the time of the study.

Funding

No funding was received for this article

Author contributions

All authors contributed to the study conception and design. Ahuva Nissim provided the oxPTM CII antibody, Christian Brenneis organized the in vivo studies and Donata Harazin optimized and performed the staining. Anne Gigout, Ahuva Nissim and Louise Topping drafted the manuscript which was critically reviewed by all authors. All authors have read and approved the final submitted manuscript.

Acknowledgement

The authors thank Andreas Westhof, Herbert Ziegler, Jennifer Freiwald, Julianne Dalchow and Nicole Ellinghaus who contributed to this work.

Authors' information

¹Osteoarthritis Research, Merck KGaA, Darmstadt, Germany, ²Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

References

1. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. *Arthritis Rheum.* 2012;64(6):1697–707.
2. Bolduc JA, Collins JA, Loeser RF. Reactive oxygen species, aging and articular cartilage homeostasis. *Free Radic Biol Med.* 2019;132:73–82.
3. Liu-Bryan R, Terkeltaub R. Emerging regulators of the inflammatory process in osteoarthritis. *Nature reviews Rheumatology.* 2015;11(1):35–44.
4. Collins JA, Diekman BO, Loeser RF. Targeting aging for disease modification in osteoarthritis. *Curr Opin Rheumatol.* 2018;30(1):101–7.
5. Henrotin YE, Bruckner P, Pujol JP. The role of reactive oxygen species in homeostasis and degradation of cartilage. *Osteoarthritis and cartilage / OARS. Osteoarthritis Research Society.* 2003;11(10):747–55.
6. Carlo MD Jr, Loeser RF. Increased oxidative stress with aging reduces chondrocyte survival: correlation with intracellular glutathione levels. *Arthritis Rheum.* 2003;48(12):3419–30.
7. Cope PJ, Ourradi K, Li Y, Sharif M. Models of osteoarthritis: the good, the bad and the promising. *Osteoarthritis and cartilage / OARS. Osteoarthritis Research Society.* 2019;27(2):230–9.
8. Aizah N, Chong PP, Kamarul T. Early Alterations of Subchondral Bone in the Rat Anterior Cruciate Ligament Transection Model of Osteoarthritis. *Cartilage.* 2019:1947603519878479.
9. Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. *Osteoarthritis and cartilage / OARS. Osteoarthritis Research Society.* 2007;15(9):1061–9.
10. Inglis JJ, McNamee KE, Chia SL, Essex D, Feldmann M, Williams RO, et al. Regulation of pain sensitivity in experimental osteoarthritis by the endogenous peripheral opioid system. *Arthritis Rheum.* 2008;58(10):3110–9.
11. Little CB, Barai A, Burkhardt D, Smith SM, Fosang AJ, Werb Z, et al. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. *Arthritis Rheum.* 2009;60(12):3723–33.
12. Hughes C, Faurholm B, Dell'Accio F, Manzo A, Seed M, Eltawil N, et al. Human single-chain variable fragment that specifically targets arthritic cartilage. *Arthritis Rheum.* 2010;62(4):1007–16.
13. Lim NH, Vincent TL, Nissim A. In vivo optical imaging of early osteoarthritis using an antibody specific to damaged arthritic cartilage. *Arthritis Res Ther.* 2015;17:376.
14. Topping LM, Thomas BL, Rhys HI, Tremoleda JL, Foster M, Seed M, et al. Targeting Extracellular Vesicles to the Arthritic Joint Using a Damaged Cartilage-Specific Antibody. *Front Immunol.* 2020;11:10.
15. Harrison JL, Williams SC, Winter G, Nissim A. Screening of phage antibody libraries. *Methods Enzymol.* 1996;267:83–109.
16. Kraus VB, Huebner JL, DeGroot J, Bendele A. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the guinea pig. *Osteoarthritis and cartilage / OARS,*

- Osteoarthritis Research Society. 2010;18 Suppl 3:S35-52.
17. Brenneis C, Westhof A, Holschbach J, Michaelis M, Guehring H, Kleinschmidt-Doerr K. Automated Tracking of Motion and Body Weight for Objective Monitoring of Rats in Colony Housing. *J Am Assoc Lab Anim Sci.* 2017;56(1):18–31.
 18. Abramson SB. Osteoarthritis and nitric oxide. *Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society.* 2008;16(Suppl 2):15–20.
 19. Iijima H, Aoyama T, Ito A, Tajino J, Nagai M, Zhang X, et al. Destabilization of the medial meniscus leads to subchondral bone defects and site-specific cartilage degeneration in an experimental rat model. *Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society.* 2014;22(7):1036-43.
 20. Zhu J, Zhu Y, Xiao W, Hu Y, Li Y. Instability and excessive mechanical loading mediate subchondral bone changes to induce osteoarthritis. *Ann Transl Med.* 2020;8(6):350.
 21. Goodwin W, McCabe D, Sauter E, Reese E, Walter M, Buckwalter JA, et al. Rotenone prevents impact-induced chondrocyte death. *Journal of orthopaedic research: official publication of the Orthopaedic Research Society.* 2010;28(8):1057–63.
 22. Arunakul M, Tochigi Y, Goetz JE, Diestelmeier BW, Heiner AD, Rudert J, et al. Replication of chronic abnormal cartilage loading by medial meniscus destabilization for modeling osteoarthritis in the rabbit knee in vivo. *Journal of orthopaedic research: official publication of the Orthopaedic Research Society.* 2013;31(10):1555–60.
 23. Yeow CH, Lau ST, Lee PV, Goh JC. Damage and degenerative changes in menisci-covered and exposed tibial osteochondral regions after simulated landing impact compression-a porcine study. *Journal of orthopaedic research: official publication of the Orthopaedic Research Society.* 2009;27(8):1100–8.
 24. Kim KS, Choi HW, Yoon HE, Kim IY. Reactive oxygen species generated by NADPH oxidase 2 and 4 are required for chondrogenic differentiation. *J Biol Chem.* 2010;285(51):40294–302.
 25. Morita K, Miyamoto T, Fujita N, Kubota Y, Ito K, Takubo K, et al. Reactive oxygen species induce chondrocyte hypertrophy in endochondral ossification. *J Exp Med.* 2007;204(7):1613–23.
 26. Aigner T, Reichenberger E, Bertling W, Kirsch T, Stoss H, von der Mark K. Type X collagen expression in osteoarthritic and rheumatoid articular cartilage. *Virchows Arch B Cell Pathol Incl Mol Pathol.* 1993;63(4):205–11.
 27. Boos N, Nerlich AG, Wiest I, von der Mark K, Ganz R, Aebi M. Immunohistochemical analysis of type-X-collagen expression in osteoarthritis of the hip joint. *Journal of orthopaedic research: official publication of the Orthopaedic Research Society.* 1999;17(4):495–502.
 28. Jiang J, Leong NL, Mung JC, Hidaka C, Lu HH. Interaction between zonal populations of articular chondrocytes suppresses chondrocyte mineralization and this process is mediated by PTHrP. *Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society.* 2008;16(1):70–82.
 29. Chery DR, Han B, Li Q, Zhou Y, Heo SJ, Kwok B, et al. Early Changes in Cartilage Pericellular Matrix Micromechanobiology Portend the Onset of Post-Traumatic Osteoarthritis. *Acta Biomater.* 2020.

30. Guilak F, Nims RJ, Dicks A, Wu CL, Meulenbelt I. Osteoarthritis as a disease of the cartilage pericellular matrix. *Matrix Biol.* 2018;71–72:40–50.

Figures




Figure 1

Histological scoring of OA for the medial tibial plateau in the ACLT+pMx and DMM models. Rat underwent ACLT+pMx or DMM surgery and were sacrificed at various timepoints (N=9-10 rats per timepoints). The ipsilateral or contralateral knees were taken for histological analysis. Slides were stained with toluidine

blue and saffron du Gatinais and scored as detailed in the Method. Histological sections for the DMM model are shown with the region selected for scoring marked in red. The total histological score is shown for both models. Data on the graphs represent the total score for each animal (N=9-10) and the mean for each timepoint and for the selected contralateral knees. ** and **** means significantly different from contralateral with $p < 0.01$ or $p < 0.0001$ respectively.




Figure 2

CX and oxPTM-CII staining of the medial tibial plateau cartilage in the ACLT+pMx and DMM models. Rat underwent ACLT+pMx or DMM surgery and were sacrificed at various timepoints (N=9-10 rats per timepoints). The knees were taken for histological analysis. Representative results for toluidine blue and saffron Gatinais as well as type X collagen (blue, CX) and oxPTM type II collagen (brown, oxPTM-CII) immunostainings are shown. For the ACLT+pMx study single immunostainings were realized. For the DMM study a CX and oxPTM-CII double staining was performed as well as an oxPTM-CII collagen single staining.




Figure 3

Partial co-localization of CX and oxPTM-CII staining in the cartilage of the medial tibial plateau and condyle in the DMM model. Rat underwent DMM surgery and were sacrificed at various timepoints (N=9-10 rats per timepoints). The knees were taken for histological analysis. Toluidin blue and saffron du Gatinais, type X collagen (blue, CX) and oxPTM type II collagen (brown, oxPTM-CII) staining are shown for cartilage of the medial tibial plateau presenting different levels of degeneration: A and B showed loss of matrix staining but no defect (both from day 14), C and D present cartilage with a small and a large defect respectively (from day 5 and 28 respectively). One example of staining for cartilage from the medial condyle is shown in E. Black arrows show examples of chondrocytes positive for oxPTM-CII but negative for CX.




Figure 4

CX and oxPTM-CII staining in the meniscus and in the growth plate. One example of a double staining for type X collagen (blue, CX) and oxPTM type II collagen (brown, oxPTM-CII) and the single staining for oxPTM-CII is shown for the growth plate and the meniscus.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [ROSCOLIARTfigures16.7.2020.docx](#)